Recent Advancement in Atypical Lipomatous Tumor Research

Mashima, Emi; Sawada, Yu; Nakamura, Motonobu

doi:10.3390/ijms22030994

Cited by 20 publications

(16 citation statements)

References 92 publications

(111 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Lipomas also appear to affect the trunk or neck more frequently. Similar data have been observed in other studies [19,20,21]. The significantly larger average size of ALTs has also been described [19,22].…”

Section: Discussionsupporting

confidence: 90%

Contrast-enhanced ultrasound reveals perfusion differences between benign lipoma and semi-malignant atypical lipomatous tumors: A prospective clinical study

Mick,

Seeberger,

Renkawitz

et al. 2023

Ultraschall Med

View full text Add to dashboard Cite

English Purpose: Soft tissue tumors (STT) are difficult to diagnose accurately, and distinguishing between benign and malignant tumors is challenging. Lipoma is the most common STT, while atypical lipomatous tumors (ALT) can dedifferentiate into malignant lipomatous tumors like grade 1 liposarcoma and require more radical therapy. This study aims to investigate the potential of contrast-enhanced ultrasound (CEUS) to differentiate between lipoma and ALT based on tumor perfusion. Materials and Methods: We prospectively examined 52 patients who were scheduled for biopsy for suspected lipoma or ALT. The CEUS examination was performed using SonoVue as a contrast agent to quantify tumor perfusion using VueBox V7.1 software. Peak enhancement (PE), rise time (RT), wash-in perfusion index (WiPI), and wash-out rate (WoR) were used to assess contrast enhancement inside the STT. Results: Among 50 tumors examined, 30 were lipomas, and 20 were ALTs. We found significant differences in perfusion between lipomas and ALTs (PE: 49.22 ± 45.75 a.u. vs. 165.67 ± 174.80; RT: 23.86 ± 20.47s vs. 10.72 ± 5.34 s; WiPI: 33.06 ± 29.94 dB vs. 107.21 ± 112.43 dB; WoR: 2.44 ± 3.70 dB/s vs. 12.75 ± 15.80 dB/s; p<.001). ROC analysis of PE resulted in a diagnostic accuracy for the detection of an ALT of 74%, and 77% for the detection of a lipoma. Conclusion: CEUS may enhance the differential diagnosis of benign lipomas and ALTs, with ALTs showing higher levels of perfusion. If larger prospective studies confirm these findings, CEUS could enhance diagnostic accuracy, guide surgical planning, and potentially reduce unnecessary treatments for patients presenting with ambiguous lipomatous tumors like lipoma or ALT. Abstract German Ziel: Die Unterscheidung zwischen gutartigen und bösartigen Weichteiltumoren gestaltet sich oftmals herausfordernd. Insbesondere benigne Lipome lassen sich nur schwer von semimalignen atypischen lipomatösen Tumoren (ALT) abgrenzen, welche in bösartige Liposarkome entdifferenzieren können. Diese Studie untersucht die Qualität des kontrastmittelverstärkten Ultraschalls (CEUS) zur Unterscheidung von Lipomen und ALT anhand der Tumormikroperfusion. Material und Methoden: 52 Patienten, bei denen bei Verdacht auf ein Lipom oder ALT eine Biopsie geplant war, wurden präoperativ mittels CEUS und MRT untersucht. Die CEUS-Tumorperfusion wurde mithilfe der Software VueBox V7.1 quantifiziert. Die Perfusionsparameter Peak enhancement (PE), rise time (RT), wash-in perfusion index (WiPI), und wash-out rate (WoR) wurden zur Beurteilung der Mikroperfusion im Tumor verwendet. Ergebnisse: 30 Lipome und 20 ALTs wurden ausgewertet. Es zeigten sich signifikante Unterschiede der Perfusionskinetik zwischen beiden Tumoren (PE: 49.22 ± 45.75 a.u. vs. 165.67 ± 174.80; RT: 23.86 ± 20.47s vs. 10.72 ± 5.34 s; WiPI: 33.06 ± 29.94 dB vs. 107.21 ± 112.43 dB; WoR: 2.44 ± 3.70 dB/s vs. 12.75 ± 15.80 dB/s; p<.001). Die CEUS-Tumorperfusion ergab nach ROC-Analyse eine Testgenauigkeit von 77% für die Erkennung eines Lipoms und von 74% für die Erkennung eines ALT. Schlussfolgerung: Die CEUS-Perfusionsanalyse ist geeignet, um gutartige Lipome und semimaligne ALTs besser abzugrenzen. ALTs zeigten signifikant höhere Perfusionswerte als Lipome. Wenn größere prospektive Studien diese Ergebnisse bestätigen, könnte CEUS die präoperative Diagnostik und somit die individuelle Therapie sowie Operationsplanung verbessern.

show abstract

Section: Discussionsupporting

confidence: 90%

Contrast-enhanced ultrasound reveals perfusion differences between benign lipoma and semi-malignant atypical lipomatous tumors: A prospective clinical study

Mick,

Seeberger,

Renkawitz

et al. 2023

Ultraschall Med

View full text Add to dashboard Cite

show abstract

“…The incidence of liposarcoma is approximately 0.7 cases per 100,000 persons per year [ 57 ]. It accounts for 0.1% of all cutaneous soft tissue sarcomas [ 21 ] and less than 20% of all soft tissue sarcomas (reviewed in [ 84 ]).…”

Section: Liposarcomamentioning

confidence: 99%

Epigenetics of Cutaneous Sarcoma

Mashima

Sawada

2021

IJMS

Self Cite

View full text Add to dashboard Cite

Epigenetic changes influence various physiological and pathological conditions in the human body. Recent advances in epigenetic studies of the skin have led to an appreciation of the importance of epigenetic modifications in skin diseases. Cutaneous sarcomas are intractable skin cancers, and there are no curative therapeutic options for the advanced forms of cutaneous sarcomas. In this review, we discuss the detailed molecular effects of epigenetic modifications on skin sarcomas, such as dermatofibrosarcoma protuberans, angiosarcoma, Kaposi’s sarcoma, leiomyosarcoma, and liposarcoma. We also discuss the application of epigenetic-targeted therapy for skin sarcomas.

show abstract

“…Recent advancements in the knowledge gained from research demonstrate the importance of epigenetic modification in the pathogenetic role of skin cancers [17][18][19]. The tumor obtains advantages in development via epigenetic modification.…”

Section: Introductionmentioning

confidence: 99%

Epigenetic Modification of PD-1/PD-L1-Mediated Cancer Immunotherapy against Melanoma

Nanamori

Sawada

2022

IJMS

Self Cite

View full text Add to dashboard Cite

Malignant melanoma is one of the representative skin cancers with unfavorable clinical behavior. Immunotherapy is currently used for the treatment, and it dramatically improves clinical outcomes in patients with advanced malignant melanoma. On the other hand, not all these patients can obtain therapeutic efficacy. To overcome this limitation of current immunotherapy, epigenetic modification is a highlighted issue for clinicians. Epigenetic modification is involved in various physiological and pathological conditions in the skin. Recent studies identified that skin cancer, especially malignant melanoma, has advantages in tumor development, indicating that epigenetic manipulation for regulation of gene expression in the tumor can be expected to result in additional therapeutic efficacy during immunotherapy. In this review, we focus on the detailed molecular mechanism of epigenetic modification in immunotherapy, especially anti-PD-1/PD-L1 antibody treatment for malignant melanoma.

show abstract

Recent Advancement in Atypical Lipomatous Tumor Research

Cited by 20 publications

References 92 publications

Contrast-enhanced ultrasound reveals perfusion differences between benign lipoma and semi-malignant atypical lipomatous tumors: A prospective clinical study

Contrast-enhanced ultrasound reveals perfusion differences between benign lipoma and semi-malignant atypical lipomatous tumors: A prospective clinical study

Epigenetics of Cutaneous Sarcoma

Epigenetic Modification of PD-1/PD-L1-Mediated Cancer Immunotherapy against Melanoma

Contact Info

Product

Resources

About